Shiraia bambusicola is an economically important medicinal fungus on bamboo. In this paper we re-describe the holotype and designate an epitype based on fresh specimens collected from Zhejiang Province in China. Morphological characters agree with those of the holotype and phylogenies based on combined partial LSU-rDNA, EF and RPB gene sequence data from the epitype, suggest that it is a new family of Pleosporales. The new family is introduced and the holotype and epitype are both illustrated.
Identification of endogenous angiogenesis inhibitors has led to development of an increasingly attractive strategy for cancer therapy and other angiogenesis-driven diseases. Vascular endothelial growth inhibitor (VEGI), a potent and relatively nontoxic endogenous angiogenesis inhibitor, has been intensively studied, and this work shed new light on developing promising anti-angiogenic strategies. It is well-documented that the RGD (Arg-Gly-Asp) motif exhibits high binding affinity to integrin α(v)β(3), which is abundantly expressed in cancer cells and specifically associated with angiogenesis on tumors. Here, we designed a fusion protein containing the special RGD-4C motif sequence and VEGI-192, aimed at offering more effective multiple targeting to tumor cells and tumor vasculature, and higher anti-angiogenic and antitumor efficacy. Functional tests demonstrated that the purified recombinant human RGD-VEGI-192 protein (rhRGD-VEGI-192) potently inhibited endothelial growth in vitro and suppressed neovascularization in chicken chorioallantoic membrane in vivo, to a higher degree as compared with rhVEGI-192 protein. More importantly, rhRGD-VEGI-192, but not rhVEGI-192 protein, could potentially target MDA-MB-435 breast tumor cells, significantly inhibiting growth of MDA-MB-435 cells in vitro, triggered apoptosis in MDA-MB-435 cells by activation of caspase-8 as well as caspase-3, which was mediated by activating the JNK signaling associated with upregulation of pro-apoptotic protein Puma, and consequently led to the observed significant antitumor effect in vivo against a human breast cancer xenograft. Our study indicated that the RGD-VEGI-192 fusion protein might represent a novel anti-angiogenic and antitumor strategy.
In this paper, a class of fractional integrodifferential equations of mixed type with time-varying generating operators and nonlocal conditions is considered. Using a contraction mapping principle and Krasnoselskii's fixed point theorem via Gronwall's inequailty, the existence and uniqueness of mild solution are given. The existence of optimal pairs of systems governed by fractional integrodifferential equations of mixed type with time-varying generating operators and nonlocal conditions is also presented.
In this paper, we study the existence and uniqueness of the P C-mild solution for a class of impulsive fractional differential equations with time-varying generating operators and nonlocal conditions. By means of the generalized Ascoli-Arzela Theorem given by us and the fixed point theorem, some existence and uniqueness results are obtained. Finally, an example is given to illustrate the theory.
Nine Colletotrichum strains were isolated from diseased and dead stalks of Hemerocallis species (daylilies) from Guizhou, Guangxi, and Liaoning provinces in China. Morphological characteristics and multilocus phylogenetic analysis of ACT, CHS I, GPDH, ITS, and TUB 2 indicate that these strains represent four taxa. Colletotrichum hemerocallidis is a new species that is described, illustrated, and compared with similar species. Colletotrichum gloeosporioides, C. liriopes, and C. spaethianum are also recorded on Hemerocallis species.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.